The underlying mechanisms of Icaritin anti-CML activity are involved in the inhibition of MAPK/ERK/JNK signals and down-regulated kinase activity of Jak-2/Stat-3/Akt signal network. Here, JAK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.